Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans

Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans is a paper indexed in PICO Portal from OpenAlex.

How many citations does Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans have?

Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans has 625 citations in the OpenAlex counts PICO Portal stores.

When was Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans published?

Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans has 2013 year in the PICO Portal index.

What is the open-access status of Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans?

Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans has bronze oa status in the PICO Portal index.

What is the DOI of Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans?

The DOI for Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans is on the source record.

What is the PMID of Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans?

The PMID for Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans is on the source record.

What is the OpenAlex record for Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans?

The OpenAlex for Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans is on the source record.